

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>.

Manuscript DOI: https://doi.org/10.2337/[insert manuscript submission number] (Example, https://doi.org/10.2337/db18-1234)	
Title:	
Author list:	
Corresponding author:	Email address:

Islet preparation	1	2	3	4	5	6	7	8 ^a
MANDATORY INFORMATION								
Unique identifier	SAMN11523048	SAMN11514696	SAMN11982795	SAMN12274306		SAMN13836615	SAMN13938639	SAMN13972304
Donor age (years)	35	59	54	37		58	50	49
Donor sex (M/F)	F	F	M	M		M	F	M
Donor BMI (kg/m ²)	33.4	21.8	42.8	25.3		23.2	39.2	34.8

Donor HbA _{1c} or other measure of blood glucose control	137.00 mg/dL	222.00 mg/dL	191.60 mg/dL	192.80 mg/dL		88.60 mg/dL	131.40 mg/dL	161.20 mg/dL
Origin/source of islets ^b	IIDP	IIDP	IIDP	IIDP		IIDP	IIDP	IIDP
Islet isolation centre	Sharp Lacy	U. Miami	U. Wisconsin	U. Miami		Sharp-Lacy	Southern California ISRC	Southern California ISRC
Donor history of diabetes? Yes/No	No	No	No	No		No	No	No
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)								
Glucose-lowering therapy at time of death ^c								

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								

Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) ^d								
Glucose-stimulated insulin secretion or other functional measurement ^e								
Handpicked to purity? Yes/No								
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results